Search the Newsreel

NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth

Novo Nordisk A/S NVO reported adjusted second-quarter 2026 earnings of 96 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 82 cents. The company had reported adjusted earnings of 90 cents per ADR in the year-ago quarter. Revenues of $12.21 …

Novo Nordisk (CPSE:NOVO B) Stock Still Looks Like A Bargain As Shares Fell 48%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the …

Novo Nordisk looks to future proof as investors worry over pipeline

View Comments

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Novo Nordisk, the Danish maker of Ozempic, experienced a significant boom in 2024, becoming Europe's largest company by market capitalization due to its successful GLP-1 weight-loss drugs. However, the article suggests that despite this success, the company may have lost its leading edge to …

Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data

Novo Nordisk's CEO acknowledged recent R&D setbacks, including mixed data for CagriSema and the failure of ziltivekimab in a phase 3 cardiovascular study. Despite CagriSema missing an endpoint in a Type 2 diabetes trial compared to Eli Lilly's tirzepatide, Novo remains optimistic about its …

Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars

Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back PREMIUM Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to …

A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype

Global scientific informatics leaders outline how the industry must conquer scientific data today to prepare for tomorrow. BASEL, Switzerland, Aug. 5, 2026 /PRNewswire/ -- Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Basel convened leading experts from companies such as Roche, Bayer, Novo Nordisk, …

Novo Nordisk falls as Wegovy sales miss, trial setback overshadow raised outlook

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) raised its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated. But shares fell 6% in U.S. trading Tuesday after the company's new Wegovy pill …

Novo Nordisk Stock Drops on Wegovy Shortfall

Novo Nordisk's U.S.-traded shares fell over 6% due to lower-than-expected sales of its new Wegovy weight-loss pill and a disappointing study result for a next-generation drug. This decline occurred despite the company pre-announcing improved overall results and an upgraded full-year 2026 financial outlook. Second-quarter …

Portal Innovations CEO John Flavin: Novo Nordisk is undervalued

John Flavin, CEO of Portal Innovations, believes that Novo Nordisk is undervalued. He shared his perspective on the company's valuation during an appearance on 'Fast Money,' where he also discussed expectations for upcoming pharma earnings. The discussion likely centered on the factors contributing to …

Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat

Novo Nordisk's shares dropped 6% despite beating Q2 earnings expectations, primarily due to a slight miss in sales for its oral Wegovy pill and lower than anticipated U.S. sales for the injectable version. The oral Wegovy miss was attributed to inventory destocking, while the …

Price to earnings forward of SANVO Fine Chemicals Group Limited – HKEX:301

Novo Nordisk (CPSE:NOVO B) Reports Mixed ZEUS Phase 3 Results For Ziltivekimab

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk has reported headline phase 3 results from the ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The study …

Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early. Continue Reading

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes. Continue Reading

Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early. Continue Reading

H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development

H1 Partnership builds on Novo Nordisk's AI and digital foundation to enhance clinical trial design and execution through AI-enabled workflows and insights H1 Partners with Novo Nordisk to Scale AI-Driven Clinical DevelopmentAriel Katz, CEO of H1 NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- …

Novo Nordisk A/S (NYSE:NVO) Announces Earnings Results

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Novo Nordisk A/S Bagsværd, 4 August 2026 - Financial report for the period 1 January 2026 to 30 June 2026 Financial performance Q2 2026 reported sales increased by 3% at CER, with growth negatively impacted by a DKK 2.6 billion rebate provision reversal related …

‘Arrogance kills’: Novo chief injects risk-taking into Ozempic maker

One year since becoming Novo Nordisk’s chief executive, Mike Doustdar is betting on the “phenomenal” sales of its weight-loss pill, new PREMIUM Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access …

The 200-Millisecond Gap in Human Conversation: Inside FinVolution's Push to Give AI a Conversational "Social Instinct"

FinVolution recently concluded its 11th Global Data Science Competition, focusing on teaching AI to understand conversational "social instincts," specifically addressing the 200-millisecond gap in human conversation. Teams competed to predict speaker intentions (continuation, turn-switching, etc.) using multimodal approaches, aiming to make AI interactions more …

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is scheduled to report its second-quarter 2026 results on Aug. 5, 2026, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.27 billion, while the same for earnings is pinned at 82 …

Novo’s late-stage IL-6 stumble shakes inflammation space

Novo Nordisk's investigational IL-6 inhibitor ziltivekimab failed to meet its primary endpoint in the Phase 3 ZEUS trial, which aimed to improve cardiovascular outcomes. This failure has significantly impacted other companies developing drugs targeting inflammation, particularly BioAge Labs and Monte Rosa Therapeutics, whose stock …

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Citi maintains a 'neutral' rating on Novo Nordisk (NYSE:NVO), believing the market's reaction to a failed heart drug trial (ziltevekimab) is excessive given its minor contribution to the company's valuation. However, ongoing concerns about pricing pressure and increasing competition in the GLP-1 obesity drug …

ZEUS delivers a bolt of pain to Novo Nordisk

Novo Nordisk's experimental cardiovascular drug, ziltivekimab, failed its phase 3 ZEUS trial, causing a 7% drop in the company's shares. The drug, an IL-6 inhibitor, did not reduce major adverse cardiovascular events despite showing expected biological activity. This setback puts pressure on Novo Nordisk …

Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Trial setback puts focus on Novo Nordisk stock Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate …

Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent Setbacks

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which …

Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial

Novo Nordisk's monoclonal antibody ziltivekimab failed to meet its primary endpoint in a Phase III trial (ZEUS) for reducing major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. Although the drug successfully engaged its target and inhibited …

Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down

Novo Nordisk's market value dropped by over $30 billion after a late-stage experimental heart drug, ziltivekimab, failed to meet its primary goals in a clinical trial. This setback prompted criticism from analysts who viewed it as a missed opportunity for the company to diversify …

Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial

Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Novo Nordisk’s Heart Drug Suffers a Major Setback. What It Means for the Stock.

The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge. Continue Reading

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

This article compares the Q1 FY2026 performance of Eli Lilly and Novo Nordisk, highlighting Lilly's significant revenue growth and raised guidance due to strong Mounjaro and Zepbound sales, contrasted with Novo Nordisk's adjusted sales decline and restructuring. While Lilly is in expansion mode with …

Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said.

Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's …

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

European stock markets closed mixed in Friday trading with the Stoxx 600 easing 0.1%, Germany's DAX adding 0.1%, the UK's FTSE 100 shedding 0.3%, France's CAC rising 0.3%, and the Swiss Market Index down 0.3%.In economic news, the Eurozone consumer price index (CPI) rose …

Novo Nordisk Stock Drops After Drug Fails in Cardiovascular Trial

Novo Nordisk's stock dropped significantly after its experimental drug, ziltivekimab, failed to reduce the risk of major adverse cardiovascular events in a late-stage trial. The Danish drugmaker's shares fell nearly 8% in Denmark and its American depositary receipts were down more than 9% in …